SECOND AMENDED AND RESTATED CREDIT AGREEMENT Dated as of September30, 2003 among WAMPOLE LABORATORIES,INC. and INVERNESS MEDICAL (UK) HOLDINGS LIMITED, as Borrowers, THE OTHER CREDIT PARTIES SIGNATORY HERETO, as Credit Parties, THE LENDERS SIGNATORY...Credit Agreement • November 14th, 2003 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
This SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this "Agreement"), dated as of September 30, 2003, is by and among INVERNESS MEDICAL INNOVATIONS, INC., a Delaware corporation ("Innovations"), WAMPOLE LABORATORIES, INC., a Delaware corporation ("US Borrower"), INVERNESS MEDICAL (UK) HOLDINGS LIMITED, a company organized under the laws of England and Wales ("European Borrower"; US Borrower and European Borrower are sometimes collectively referred to as "Borrowers" and individually as a "Borrower"), the other Credit Parties signatory hereto, the Lenders signatory hereto from time to time, GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation, as administrative agent for Lenders, MERRILL LYNCH CAPITAL, a division of Merrill Lynch Business Financial Services Inc. ("ML Capital"), as documentation agent and co-syndication agent, UBS SECURITIES LLC, as co-syndication agent, and GECC CAPITAL MARKETS GROUP, INC. and ML CAPITAL, as co-lead arrangers.
